scholarly journals Infectious Agents Are Not Necessary for Murine Atherogenesis

2000 ◽  
Vol 191 (8) ◽  
pp. 1437-1442 ◽  
Author(s):  
Samuel D. Wright ◽  
Charlotte Burton ◽  
Melba Hernandez ◽  
Heide Hassing ◽  
Judy Montenegro ◽  
...  

Recent work has revealed correlations between bacterial or viral infections and atherosclerotic disease. One particular bacterium, Chlamydia pneumoniae, has been observed at high frequency in human atherosclerotic lesions, prompting the hypothesis that infectious agents may be necessary for the initiation or progression of atherosclerosis. To determine if responses to gram-negative bacteria are necessary for atherogenesis, we first bred atherosclerosis-prone apolipoprotein (apo) E−/− (deficient) mice with animals incapable of responding to bacterial lipopolysaccharide. Atherogenesis was unaffected in doubly deficient animals. We further tested the role of infectious agents by creating a colony of germ-free apo E−/− mice. These animals are free of all microbial agents (bacterial, viral, and fungal). Atherosclerosis in germ-free animals was not measurably different from that in animals raised with ambient levels of microbial challenge. These studies show that infection is not necessary for murine atherosclerosis and that, unlike peptic ulcer, Koch's postulates cannot be fulfilled for any infectious agent in atherosclerosis.

2008 ◽  
Vol 114 (8) ◽  
pp. 509-531 ◽  
Author(s):  
Caroline Watson ◽  
Nicholas J. Alp

Cardiovascular disease, resulting from atherosclerosis, is a leading cause of global morbidity and mortality. Genetic predisposition and classical environmental risk factors explain much of the attributable risk for cardiovascular events in populations, but other risk factors for the development and progression of atherosclerosis, which can be identified and modified, may be important therapeutic targets. Infectious agents, such as Chlamydia pneumoniae, have been proposed as contributory factors in the pathogenesis of atherosclerosis. In the present review, we consider the experimental evidence that has accumulated over the last 20 years evaluating the role of C. pneumoniae in atherosclerosis and suggest areas for future research in this field.


2010 ◽  
Vol 2 (1) ◽  
pp. e2010022 ◽  
Author(s):  
Eligio Pizzigallo ◽  
Delia Racciatti ◽  
Valeria Gorgoretti

The infection from Epstein-Barr virus (EBV) or virus of infectious mononucleosis, together with other herpesviruses’ infections, represents a prototype of persistent viral infections characterized by the property of the latency. Although the reactivations of the latent infection are associated with the resumption of the viral replication and eventually with the “shedding”, it is still not clear if this virus can determine chronic infectious diseases, more or less evolutive. These diseases could include some pathological conditions actually defined as “idiopathic”and characterized by the “viral persistence” as the more credible pathogenetic factor. Among the so-called idiopathic syndromes, the “chronic fatigue syndrome” (CFS) aroused a great interest around the eighties of the last century when, just for its relationship with EBV, it was called “chronic mononucleosis” or “chronic EBV infection”. Today CFS, as defined in 1994 by the CDC of Atlanta (USA), really represents a multifactorial syndrome characterized by a chronic course, where reactivation and remission phases alternate, and by a good prognosis. The etiopathogenetic role of EBV is demonstrated only in a well-examined subgroup of patients, while in most of the remaining cases this role should be played by other infectious agents - able to remain in a latent or persistent way in the host – or even by not infectious agents (toxic, neuroendocrine, methabolic, etc.). However, the pathogenetic substrate of the different etiologic forms seems to be the same, much probably represented by the oxidative damage due to the release of pro-inflammatory cytokines as a response to the triggering event (infectious or not infectious). Anyway, recently the scientists turned their’s attention to the genetic predisposition of the subjects affected by the syndrome, so that in the last years the genetic studies, together with those of molecular biology, received a great impulse. Thanks to both these studies it was possibile to confirm the etiologic links between the syndrome and EBV or other herpesviruses or other persistent infectious agents. The mechanisms of EBV latency have been carefully examined both because they represent the virus strategy to elude the response of the immune system of the host, and because they are correlated with those oncologic conditions associated to the viral persistence, particularly lymphomas and lymphoproliferative disorders. Just these malignancies, for which a pathogenetic role of EBV is clearly documented, should represent the main clinical expression of a first group of chronic EBV infections characterized by a natural history where the neoplastic event aroused from the viral persistence in the resting B cells for all the life, from the genetic predisposition of the host and from the oncogenic potentialities of the virus that chronically persists and incurs reactivations. Really, these oncological diseases should be considered more complications than chronic forms of the illness, as well as other malignancies for which a viral – or even infectious - etiology is well recognized. The chronic diseases, in fact, should be linked in a pathogenetic and temporal way to the acute infection, from whom start the natural history of the following disease. So, as for the chronic liver diseases from HBV and HCV, it was conied the acronym of CAEBV (Chronic Active EBV infection), distinguishing within these pathologies the more severe forms (SCAEBV) mostly reported in Far East and among children or adolescents. Probably only these forms have to be considered expressions of a chronic EBV infection “sensu scrictu”, together with those forms of CFS where the etiopathogenetic and temporal link with the acute EBV infection is well documented. As for CFS, also for CAEBV the criteria for a case definition were defined, even on the basis of serological and virological findings. However, the lymphoproliferative disorders are excluded from these forms and mantain their nosographic (e.g. T or B cell or NK type lymphomas) and pathogenetic collocation, even when they occur within chronic forms of EBV infection. In the pathogenesis, near to the programs of latency of the virus, the genetic and environmental factors, independent from the real natural history of EBV infection, play a crucial role. Finally, it was realized a review of cases - not much numerous in literature – of chronic EBV infection associated to chronic liver and neurological diseases, where the modern techniques of molecular biology should be useful to obtain a more exact etiologic definition, not always possibile to reach in the past. The wide variety of clinical forms associated to the EBV chronic infection makes difficult the finding of a univocal pathogenetic link. There is no doubt, however, that a careful examination of the different clinical forms described in this review should be useful to open new horizons to the study of the persistent viral infections and the still not well cleared pathologies that they can induce in the human host. 


2002 ◽  
Vol 15 (1) ◽  
pp. 1-20 ◽  
Author(s):  
Jens Boman ◽  
Margaret R. Hammerschlag

SUMMARY A number of studies have found that inflammation of the vessel wall plays an essential role in both the initiation and progression of atherosclerosis and erosion and fissure and the eventual rupture of plaques. Chlamydia pneumoniae is one of the infectious agents that have been investigated as possible causes of this inflammation. Initial studies of the association of C. pneumoniae and cardiovascular disease (CVD) were seroepidemiologic, and these were followed by studies in which the organism was identified in vascular tissue from patients with CVD by electron microscopy, PCR and immunocytochemical staining (ICC). C. pneumoniae has also been isolated by culture from vascular tissue in a small number patients. However, no single serologic, PCR, or ICC assay has been used consistently across all studies. The assays used are also not standardized. Recent studies of serologic and PCR assays for diagnosis of C. pneumoniae infection have suggested that there may be substantial interlaboratory variation in the performance of these tests. It now appears that some of the inconsistency of results from study to study may be due, in part, to lack of standardized methods. Although initial seroepi-demiologic studies demonstrated a significantly increased risk of adverse cardiac outcome in patients who were seropositive, subsequent prospective studies found either small or no in-creased risk. In addition to the lack of consistent serologic criteria, recent evaluations have demonstrated inherent problems with performance of the most widely used serologic methods. Most importantly, we do not have a reliable serologic marker for chronic or persistent C. pneumoniae infection.


2004 ◽  
Vol 78 (13) ◽  
pp. 7148-7152 ◽  
Author(s):  
Sophie Paquet ◽  
Elifsu Sabuncu ◽  
Jean-Louis Delaunay ◽  
Hubert Laude ◽  
Didier Vilette

ABSTRACT During prion infections, the cellular glycosylphosphatidylinositol-anchored glycoprotein PrP is converted into a conformational isoform. This abnormal conformer is thought to recruit and convert the normal cellular PrP into a likeness of itself and is proposed to be the infectious agent. We investigated the distribution of the PrP protein on the surface of Rov cells, an epithelial cell line highly permissive to prion multiplication, and we found that PrP is primarily expressed on the apical side. We further show that prion transmission to Rov cells is much more efficient if infectivity contacts the apical side, indicating that the apical and basolateral sides of Rov cells are not equally competent for prion infection and adding prions to the list of the conventional infectious agents (viruses and bacteria) that infect epithelial cells in a polarized manner. These data raise the possibility that apically expressed PrP may be involved in this polarized process of infection. This would add further support for a crucial role of PrP at the cell surface in prion infection of target cells.


Author(s):  
Nazaret Peña-Gil ◽  
Cristina Santiso-Bellón ◽  
Roberto Gozalbo-Rovira ◽  
Javier Buesa ◽  
Vicente Monedero ◽  
...  

Rotavirus (RV) and norovirus (NoV) are the leading cause of acute gastroenteritis (AGE) worldwide. Several studies have demonstrated that histo-blood group antigens (HBGAs) have a role in NoV and RV infections, since their presence on the gut epithelial surfaces is essential for the susceptibility to many NoV and RV genotypes. Polymorphisms in genes that code for enzymes required for HBGAs synthesis lead to secretor or non-secretor and Lewis positive and Lewis negative individuals. While secretor individuals appear to be more susceptible to RV infections, regarding NoVs infections there are too many discrepancies that prevent drawing conclusions. A second factor that influences enteric viral infections is the gut microbiota of the host. In vitro and animal studies have determined that the gut microbiota limits, but in some cases enhances, enteric viral infection. The ways microbiota can enhance NoV or RV infection include virion stabilization and promotion of virus attachment to host cells, whereas experiments with microbiota-depleted and germ-free animals point to immunoregulation as the mechanism by which the microbiota restricts infection. Human trials with live, attenuated RV vaccines and analysis of the microbiota in responders and non-responders individuals also allowed the identification of bacterial taxa linked to vaccine efficacy. As more information is gained on the complex relationships that are established between the host (glycobiology and immune system), the gut microbiota and the intestinal viruses, new avenues will be open for the development of novel anti-NoV and anti-RV therapies.


2021 ◽  
Vol 22 (24) ◽  
pp. 13473
Author(s):  
Nazaret Peña-Gil ◽  
Cristina Santiso-Bellón ◽  
Roberto Gozalbo-Rovira ◽  
Javier Buesa ◽  
Vicente Monedero ◽  
...  

Rotavirus (RV) and norovirus (NoV) are the leading causes of acute gastroenteritis (AGE) worldwide. Several studies have demonstrated that histo-blood group antigens (HBGAs) have a role in NoV and RV infections since their presence on the gut epithelial surfaces is essential for the susceptibility to many NoV and RV genotypes. Polymorphisms in genes that code for enzymes required for HBGAs synthesis lead to secretor or non-secretor and Lewis positive or Lewis negative individuals. While secretor individuals appear to be more susceptible to RV infections, regarding NoVs infections, there are too many discrepancies that prevent the ability to draw conclusions. A second factor that influences enteric viral infections is the gut microbiota of the host. In vitro and animal studies have determined that the gut microbiota limits, but in some cases enhances enteric viral infection. The ways that microbiota can enhance NoV or RV infection include virion stabilization and promotion of virus attachment to host cells, whereas experiments with microbiota-depleted and germ-free animals point to immunoregulation as the mechanism by which the microbiota restrict infection. Human trials with live, attenuated RV vaccines and analysis of the microbiota in responder and non-responder individuals also allowed the identification of bacterial taxa linked to vaccine efficacy. As more information is gained on the complex relationships that are established between the host (glycobiology and immune system), the gut microbiota and intestinal viruses, new avenues will open for the development of novel anti-NoV and anti-RV therapies.


Author(s):  
Ghadeer A. R. Y. Suaifan ◽  
Bayan A. Alkhawaja ◽  
Aya A. M. Mohammed

: Coronaviruses are RNA-infective viruses that could be considered principal players in universal high-profile outbreaks, namely the Severe Acute Respiratory Syndrome (SARS, 2002-2003), the Middle East Respiratory Syndrome (MERS, 2012) and the continuing novel coronavirus disease (COVID-19, 2019) pandemic. RNA coronaviruses infections raise public health concerns with infections’ severity ranging from serious pandemics and highly contagious infections to common influenza episodes. With a wide consensus concerning the seminal role of early detection of the infectious agent on the clinical prognosis, recent technological endeavors have facilitated the rapid, sensitive and specific diagnosis of viral infections. Given that the burst of confirmed cases of the novel coronavirus disease 2019 (COVID-19) are climbing steeply, and we are amid this pandemic, this work will center at the respiratory RNA-viruses outbreaks, including the three coronaviruses-related pandemics, emphasizing on the approved diagnostic approaches, outlining therapeutic clinical trials as well as vaccine candidates. Based on the accumulated data and knowledge on the previous RNA-virus outbreaks, this review aspires to link the current intervention measures against SARS-CoV-2 infection with the previous interventions and to provide a roadmap for any possible future measures.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 3771-3771
Author(s):  
Stephen Starko Francis ◽  
Jake Wendt ◽  
Amelia D. Wallace ◽  
Lee W Riley ◽  
Fenyong Liu ◽  
...  

Abstract Purpose: To describe and compare the pre-treatment bone marrow metagenomes of childhood acute lymphoblastic leukemia (ALL) and childhood acute myeloid leukemia (AML). Background: Leukemia is the most common cancer in children, comprised mainly of ALL (~80%) followed by AML (~17%). The role of infections and their timing in the etiology of pre B-cell ALL's (but not AML's) is supported by a considerable body of epidemiologic evidence developed in the past 20 years (Gilham, Peto et al. 2005, Ma, Urayama et al. 2009). There are two main infection related hypotheses. Greaves postulates that delayed infection, akin to the hygiene hypothesis, increases risk of leukemia (Greaves and Alexander 1993, Greaves 1997). The second hypothesis set forth by Kinlen is not mutually exclusive and postulates the role of a transforming yet common virus where introduction of the infectious agent to previously naive communities trigger leukemia (Kinlen 1995). While many viral agents have been investigated (reviewed in (O'Connor and Boneva 2007)) no definitive infectious agent has been identified but, until recently, broad surveys of the microbiome were not possible. Recent developments in next generation sequencing and bioinformatics now allow for unbiased investigation into the totality of organisms that inhabit the human body. Methods: Pre-treatment bone marrow specimens were collected in pre B-cell ALL and AML cases participating in the California Childhood Leukemia Study. AML's with similar age distribution to the ALL's were utilized as controls, to represent the infection history of an immune suppressed child. We interrogated the viral metagenomes of 60 ALL’s and 30 AML’s, pooled and reduced with ribosomal capture, then sequenced with high coverage next generation RNA sequencing on an Illumina HiSeq 2500. The resulting sequences were analyzed using a custom bioinformatics pipeline, DARK, to remove human sequences, to identify viral transcripts, and to categorize all transcripts present in the pre-treatment bone marrow. Bacterial metagenomes of the same subjects were analyzed using 16S rRNA amplicon sequencing and the QIIME pipeline. Results: We analyzed over 500 million 100bp reads and categorized human, non-human and unknown sequences. We found striking differences between the viral metagenomes of childhood ALL and AML, with ALL subjects presenting with a greater viral infection load than AML’s. Furthermore, differences in the presence of transcripts aligning to both exogenous viruses and endogenous retroviruses were observed with some viruses occurring exclusively in ALL’s. We found no difference between the bacterial metagenomes of childhood ALL and AML suggesting no differential contamination occurred during collection and analysis. Discussion: This study provides the first measurement of all identifiable infectious agents in both childhood ALL an AML. Our data suggest that bacteria do not play a role in the etiology of ALL. The greater number and frequency of viral infectious agents were observed in ALL versus AML contribute to an etiologic hypothesis of ALL involving viral infections yet require replication and additional follow up. Moreover the clinical relevance of these infections and their relation to outcome should be investigated. References Gilham, C., J. Peto, J. Simpson, E. Roman, T. O. Eden, M. F. Greaves, F. E. Alexander and U. Investigators (2005). "Day care in infancy and risk of childhood acute lymphoblastic leukaemia: findings from UK case-control study." BMJ 330(7503): 1294. Greaves, M. F. (1997). "Aetiology of acute leukaemia." Lancet 349(9048): 344-349. Greaves, M. F. and F. E. Alexander (1993). "An infectious etiology for common acute lymphoblastic leukemia in childhood?" Leukemia 7(3): 349-360. Kinlen, L. J. (1995). "Epidemiological evidence for an infective basis in childhood leukaemia." Br J Cancer 71(1): 1-5. Ma, X., K. Urayama, J. Chang, J. L. Wiemels and P. A. Buffler (2009). "Infection and pediatric acute lymphoblastic leukemia." Blood Cells Mol Dis 42(2): 117-120. O'Connor, S. M. and R. S. Boneva (2007). "Infectious etiologies of childhood leukemia: plausibility and challenges to proof." Environ Health Perspect 115(1): 146-150. Disclosures No relevant conflicts of interest to declare.


2015 ◽  
Vol 2015 ◽  
pp. 1-12 ◽  
Author(s):  
Luiza A. Rabelo ◽  
Fernanda O. Ferreira ◽  
Valéria Nunes-Souza ◽  
Lucas José Sá da Fonseca ◽  
Marília O. F. Goulart

Arginase is a metalloenzyme which hydrolyzes L-arginine to L-ornithine and urea. Since its discovery, in the early 1900s, this enzyme has gained increasing attention, as literature reports have progressively pointed to its critical participation in regulating nitric oxide bioavailability. Indeed, accumulating evidence in the following years would picture arginase as a key player in vascular health. Recent studies have highlighted the arginase regulatory role in the progression of atherosclerosis, the latter an essentially prooxidant state. Apart from the fact that arginase has been proven to impair different metabolic pathways, and also as a consequence of this, the repercussions of the actions of such enzyme go further than first thought. In fact, such metalloenzyme exhibits direct implications in multiple cardiometabolic diseases, among which are hypertension, type 2 diabetes, and hypercholesterolemia. Considering the epidemiological repercussions of these clinical conditions, arginase is currently seen under the spotlights of the search for developing specific inhibitors, in order to mitigate its deleterious effects. That said, the present review focuses on the role of arginase in endothelial function and its participation in the establishment of atherosclerotic lesions, discussing the main regulatory mechanisms of the enzyme, also highlighting the potential development of pharmacological strategies in related cardiovascular diseases.


2020 ◽  
Vol 2020 ◽  
pp. 1-15
Author(s):  
Shengjie Yang ◽  
Min Wu ◽  
Xiaoya Li ◽  
Ran Zhao ◽  
Yixi Zhao ◽  
...  

Endoplasmic reticulum (ER) stress is closely associated with atherosclerosis and related cardiovascular diseases (CVDs). It occurs due to various pathological factors that interfere with ER homeostasis, resulting in the accumulation of unfolded or misfolded proteins in the ER lumen, thereby causing ER dysfunction. Here, we discuss the role of ER stress in different types of cells in atherosclerotic lesions. This discussion includes the activation of apoptotic and inflammatory pathways induced by prolonged ER stress, especially in advanced lesional macrophages and endothelial cells (ECs), as well as common atherosclerosis-related ER stressors in different lesional cells, which all contribute to the clinical progression of atherosclerosis. In view of the important role of ER stress and the unfolded protein response (UPR) signaling pathways in atherosclerosis and CVDs, targeting these processes to reduce ER stress may be a novel therapeutic strategy.


Sign in / Sign up

Export Citation Format

Share Document